학술논문

LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance
Document Type
Report
Source
Journal of Clinical Investigation. December 15, 2021, Vol. 131 Issue 24
Subject
United States
Language
English
ISSN
0021-9738
Abstract
Dysregulation in adipokine biosynthesis and function contributes to obesity- induced metabolic diseases. However, the identities and functions of many of the obesity-induced secretory molecules remain unknown. Here, we report the identification of leucine-rich alpha-2-glycoprotein 1 (LRG1) as an obesity- associated adipokine that exacerbates high fat diet-induced hepatosteatosis and insulin resistance. Serum levels of LRG1 were markedly elevated in obese humans and mice compared with their respective controls. LRG1 deficiency in mice greatly alleviated diet-induced hepatosteatosis, obesity, and insulin resistance. Mechanistically, LRG1 bound with high selectivity to the liver and promoted hepatosteatosis by increasing de novo lipogenesis and suppressing fatty acid p-oxidation. LRG1 also inhibited hepatic insulin signaling by downregulating insulin receptor substrates 1 and 2. Our study identified LRG1 as a key molecule that mediates the crosstalk between adipocytes and hepatocytes in diet-induced hepatosteatosis and insulin resistance. Suppressing LRG1 expression and function may be a promising strategy for the treatment of obesity-related metabolic diseases.
Introduction Adipose tissue dysfunction plays a critical role in the development of insulin resistance (IR), a major risk factor for type 2 diabetes, fatty liver diseases, and cardiovascular complication (1, [...]